Screening services for human iPSC-derived cells
Axol Bioscience has expanded its service offering with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells.
The new services have been developed to support preclinical research by optimising hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.
As part of the new services, Axol is incorporating the Maestro Pro, a market-leading MEA platform from Axion Biosystems. This will allow customers to benefit from Axol’s extensive catalogue of hiPSC-derived cells and in-house electrophysiology expertise, in combination with Axion’s most advanced offering.
Axol’s MEA screening service will include:
- recording of field action potentials from neurons and cardiomyocytes
- local extracellular action potential (LEAP) and contractility recordings from cardiomyocytes
- cell visualisation and multiplexing for microscopy and calcium imaging assays
- targeted panel compound and new chemical entity (NCE) screening
- cardiotoxicity and neurotoxicity testing
- cell, co-culture and disease model validation
- long-term cell proliferation studies
- bespoke projects and pilot studies.
The launch of Axol’s services follows the recent appointment of Liam Taylor as CEO at Axol, and forms part of the company’s strategy to grow its iPSC technologies, products and services.
The British In Vitro Diagnostics Association represents the IVD Industry in the UK, to Government, professional bodies, the public, and at MedTech Europe. Giving support to members on regulatory issues, BIVDA also promotes the clinical and cost utility of IVDs in the provision of effective healthcare, both in acute diagnosis and in the prediction...